2024;134(2):xxxxx
2022 DOI: 10.1016/S0140-6736(22)02033-5 PMID: 36354040 Read on PubMed The Lancet Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Rosenstock J, Frias J, Jastreboff AM, et al
Additional information Competing interests The authors declare that they have no competing interests
Patients who value continuity of care will feel like they are starting over with each provider exchange
While effective, CPAP adherence remains a persistent challenge, and the therapy does not address the metabolic and inflammatory pathways that often contribute to OSA severity